Research advances on baicalin and baicalein as potential therapeutic agents for fibrotic disease

Zhongguo Zhongyao Zazhi

Volumn 42, Issue 7, 2017, Pages 1271-1276

  Zhu, Qing Jun ^a  

^a SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Anti fibrosis; Baicalein; Baicalin; Organ fibrosis

Indexed keywords

BAICALEIN; BAICALIN; CYTOKINE; FLAVANONE DERIVATIVE; FLAVONOID;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TRANSFORMATION; FIBROSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; HUMAN;

FIBROSIS; FLAVANONES; FLAVONOIDS; HUMANS;

EID: 85041562295     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis[J]. Am J Physiol Cell Physiol, 2013, 304(3): 216.
2. Pang H, Xue W, Shi A, et al. Multiple-ascending-dose pharmacokinetics and safety evaluation of baicalein chewable tablets in healthy Chinese volunteers[J]. Clin Drug Investig, 2016, 36(9): 713.
3. Li M, Shi A, Pang H, et al. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects[J]. J Ethnopharmacol, 2014, 156: 210.
4. Tian S, He G, Song J, et al. Pharmacokinetic study of baicalein after oral administration in monkeys[J]. Fitoterapia, 2012, 83(3): 532.
5. Srinivas N R. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives[J]. Xenobiotica, 2010, 40(5): 357.
6. Yang M D, Deng Q G, Chen S, et al. Hepatoprotective mechanisms of Yan-gan-wan[J]. Hepatol Res, 2005, 32(4): 202.
7. Ono M, Miyamura M, Kyotani S, et al. Effects of Sho-saiko-to extract on liver fibrosis in relation to the changes in hydroxyproline and retinoid levels of the liver in rats[J]. J Pharm Pharmacol, 1999, 51(9): 1079.
8. Yang M D, Chiang Y M, Higashiyama R, et al. Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor gamma in hepatic stellate cells for their antifibrotic effect[J]. Hepatology, 2012, 55(4): 1271.
9. Peng X D, Dai L L, Huang C Q, et al. Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis[J]. World J Gastroenterol, 2009, 15(37): 4720.
10. Qiao H, Han H, Hong D, et al. Protective effects of baicalin on carbon tetrachloride induced liver injury by activating PPARgamma and inhibiting TGFbeta1[J]. Pharm Biol, 2011, 49(1): 38.
11. 4 liver fibrosis model in rats[J]. Eur J Pharmacol, 2010, 631(1/3): 53.
12. Inoue T, Jackson E K. Strong antiproliferative effects of baicalein in cultured rat hepatic stellate cells[J]. Eur J Pharmacol, 1999, 378(1): 129.
13. Zhao Y, Li H, Gao Z, et al. Effects of dietary baicalin supplementation on iron overload-induced mouse liver oxidative injury[J]. Eur J Pharmacol, 2005, 509(2/3): 195.
14. Qiao H, Tong Y, Han H, et al. A novel therapeutic regimen for hepatic fibrosis using the combination of mesenchymal stem cells and baicalin[J]. Pharmazie, 2011, 66(1): 37.
15. Borensztajn K, Crestani B, Kolb M. Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers-insights from the bench side[J]. Respiration, 2013, 86(6): 441.
16. Betensley A, Sharif R, Karamichos D. A systematic review of the role of dysfunctional wound healing in the pathogenesis and treatment of idiopathic pulmonary fibrosis[J]. J Clin Med, 2017, doi: 10.3390/jcm6010002.
17. Gao Y, Lu J, Zhang Y, et al. Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21[J]. Pulm Pharmacol Ther, 2013, 26(6): 649.
18. Hu C, Wang Y, Fan Y, et al. Lipidomics revealed idiopathic pulmonary fibrosis-induced hepatic lipid disorders corrected with treatment of baicalin in a murine model[J]. AAPS J, 2015, 17(3): 711.
19. Huang X, He Y, Chen Y, et al. Baicalin attenuates bleomycin-induced pulmonary fibrosis via adenosine A2a receptor related TGF-beta1-induced ERK1/2 signaling pathway[J]. BMC Pulm Med, 2016, 16(1): 132.
20. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis[J]. J Exp Med, 2010, 207(8): 1589.
21. Scheibner K A, Boodoo S, Collins S, et al. The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion[J]. Am J Respir Cell Mol Biol, 2009, 40(3): 251.
22. Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis[J]. Cytokine Growth Factor Rev, 2008, 19(2): 133.
23. Pan L H, Yamauchi K, Uzuki M, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF[J]. Eur Respir J, 2001, 17(6): 1220.
24. Moran J M, Ortiz-Ortiz M A, Ruiz-Mesa L M, et al. Nitric oxide in paraquat-mediated toxicity: a review[J]. J Biochem Mol Toxicol, 2010, 24(6): 402.
25. Mainwaring G, Lim F L, Antrobus K, et al. Identification of early molecular pathways affected by paraquat in rat lung[J]. Toxicology, 2006, 225(2/3): 157.
26. Liu T, Dai W, Li C, et al. Baicalin alleviates silica-induced lung inflammation and fibrosis by inhibiting the Th17 response in C57BL/6 mice[J]. J Nat Prod, 2015, 78(12): 3049.
27. O'Donnell M P. Renal tubulointerstitial fibrosis. New thoughts on its development and progression[J]. Postgrad Med, 2000, 108(1): 159.
28. Hu Q, Noor M, Wong Y F, et al. In vitro anti-fibrotic activities of herbal compounds and herbs[J]. Nephrol Dial Transplant, 2009, 24(10): 3033.
29. Wang W, Zhou P H, Xu C G, et al. Baicalein ameliorates renal interstitial fibrosis by inducing myofibroblast apoptosis in vivo and in vitro[J]. BJU Int, 2015, 118(1): 145.
30. Wang W, Zhou P H, Xu C G, et al. Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-kappaB and MAPK signal pathways[J]. J Mol Histol, 2015, 46(3): 283.
31. Sirin Y, Susztak K. Notch in the kidney: development and disease[J]. J Pathol, 2011, 226(2): 394.
32. Sweetwyne M T, Tao J, Susztak K. Kick it up a notch: notch signaling and kidney fibrosis[J]. Kidney Int Suppl, 2011, 4(1): 91.
33. Yu C M, Tipoe G L, Wing-Hon L K, et al. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction[J]. J Am Coll Cardiol, 2001, 38(4): 1207.
34. Leask A. Getting to the heart of the matter new insights into cardiac fibrosis[J]. Circ Res, 2015, 116(7): 1269.
35. Travers J G, Kamal F A, Robbins J, et al. Cardiac fibrosis: the fibroblast awakens[J]. Circ Res, 2016, 118(6): 1021.
36. Matsubara L S, Matsubara B B, Okoshi M P, et al. Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats[J]. Can J Physiol Pharmacol, 1997, 75(12): 1328.
37. 2+/calmodulin-dependent transactivation of epidermal growth factor receptor[J]. Circ Res, 1998, 82(12): 1338.
38. Wen Y, Gu J, Liu Y, et al. Overexpression of 12-lipoxygenase causes cardiac fibroblast cell growth[J]. Circ Res, 2001, 88(1): 70.
39. Wen Y, Nadler J L, Gonzales N, et al. Mechanisms of Ang II-induced mitogenic responses: role of 12-lipoxygenase and biphasic MAP kinase[J]. Am J Physiol, 1996, 271(41): 1212.
40. Kong E K, Huang Y, Sanderson J E, et al. Baicalein and wogonin inhibit collagen deposition in SHR and WKY cardiac fibroblast cultures[J]. BMB Rep, 2010, 43(4): 297.
41. Kong E K, Yu S, Sanderson J E, et al. A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensive rats[J]. Eur J Pharmacol, 2011, 658(2/3): 175.
42. Lorenz K, Schmitt J P, Schmitteckert E M, et al. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy[J]. Nat Med, 2009, 15(1): 75.
43. Akazawa H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy[J]. Circ Res, 2003, 92(10): 1079.
44. Zong J, Zhang D P, Zhou H, et al. Baicalein protects against cardiac hypertrophy through blocking MEK-ERK1/2 signaling[J]. J Cell Biochem, 2012, 114(5): 1058.
45. Zhao F, Fu L, Yang W, et al. Cardioprotective effects of baicalein on heart failure via modulation of Ca(2+) handling proteins in vivo and in vitro[J]. Life Sci, 2015, 145: 213.
46. 2+handling in heart failure[J]. J Clin Invest, 2005, 115(3): 556.
47. Butter C, Rastogi S, Minden H H, et al. Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure[J]. J Am Coll Cardiol, 2008, 51(18): 1784.
48. Zhang T, Maier L S, Dalton N D, et al. The delta C isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure[J]. Circ Res, 2003, 92(8): 912.
49. Garg S, Narula J, Chandrashekhar Y. Apoptosis and heart failure: clinical relevance and therapeutic target[J]. J Mol Cell Cardiol, 2005, 38(1): 73.
50. Wang A W, Song L, Miao J, et al. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-kappaB, and calcineurin signaling pathways in mice[J]. Am J Hypertens, 2014, 28(4): 518.